Bioclinica Launches Post-Approval Research Division
Bioclinica has built a post-approval study-specific technology platform along with a Program Coordinating Center (PCC) with dedicated and experienced post-approval research staff.
Bioclinica®, a specialty clinical trials services and technology provider, has created a Post-Approval Research division of its Global Clinical Research business segment to meet the growing and ever-evolving needs of the post-approval research industry. Leveraging its technology expertise, Bioclinica has built a post-approval study-specific technology platform along with a Program Coordinating Center (PCC) with dedicated and experienced post-approval research staff. The PCC provides global operational infrastructure from centralized locations to support local languages and time differences. In addition, a unique service offering of the Post-Approval Research division is the development of the Patient Outreach Center (POC).
Read the full release.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
Optimizing Phase III Oncology Trial Recruitment with Data-Driven Insights
February 3rd 2025A pharmaceutical company aimed to launch a Phase III clinical trial for a new oncology drug, focusing on efficient and effective patient recruitment across diverse regions. They evaluated patient populations by analyzing demographics, social determinants of health, and geography. Investigator profiling included practice details, affiliations, referral networks, and clinical trial experience. The final step involved selecting and extracting target lists for implementation.
